uniQure (NASDAQ:QURE) Short Interest Update

uniQure (NASDAQ:QURE) was the target of a significant drop in short interest in February. As of February 15th, there was short interest totalling 2,440,000 shares, a drop of 23.8% from the January 31st total of 3,200,000 shares. Based on an average daily volume of 2,150,000 shares, the short-interest ratio is currently 1.1 days.

uniQure Trading Down 17.1 %

Shares of QURE stock opened at $10.90 on Tuesday. uniQure has a 12-month low of $3.73 and a 12-month high of $19.18. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm’s 50 day moving average is $14.92 and its 200 day moving average is $9.86. The stock has a market capitalization of $531.30 million, a P/E ratio of -2.20 and a beta of 0.38.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Leerink Partners increased their price target on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a report on Wednesday, December 11th. HC Wainwright increased their price target on shares of uniQure from $25.00 to $70.00 and gave the company a “buy” rating in a report on Monday, January 27th. StockNews.com upgraded shares of uniQure to a “sell” rating in a report on Wednesday, February 5th. The Goldman Sachs Group increased their price target on shares of uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a report on Thursday, December 12th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $24.00 price target on shares of uniQure in a report on Tuesday, January 21st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, uniQure currently has a consensus rating of “Moderate Buy” and an average target price of $38.89.

Insider Buying and Selling at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the transaction, the chief executive officer now owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Christian Klemt sold 14,341 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $153,448.70. Following the transaction, the chief financial officer now directly owns 152,372 shares of the company’s stock, valued at $1,630,380.40. This represents a 8.60 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 55,915 shares of company stock valued at $588,112. Corporate insiders own 4.74% of the company’s stock.

Institutional Investors Weigh In On uniQure

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. raised its position in uniQure by 9.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock worth $195,000 after acquiring an additional 969 shares during the period. Tudor Investment Corp ET AL raised its position in uniQure by 5.9% in the fourth quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company’s stock worth $438,000 after acquiring an additional 1,371 shares during the period. Wells Fargo & Company MN raised its position in uniQure by 13.9% in the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock worth $217,000 after acquiring an additional 1,503 shares during the period. Northern Trust Corp raised its position in uniQure by 2.1% in the fourth quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company’s stock worth $1,688,000 after acquiring an additional 1,923 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in uniQure by 6.0% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company’s stock worth $1,253,000 after acquiring an additional 3,996 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.